Biomedical Research

Objective: To observe and analyze the influence of carbamazepine-phenobarbital combined treatment on IL-1β, IL-6, Bcl-2, and Bax expression levels in children with epilepsy.

Method: A total of 94 children with epilepsy in our hospital from January 2015 to September 2016 were selected and equally divided into an observation group (n=47) and a control group (n=47) through random number table. Children in the control group were given only carbamazepine tablets, whereas those in the observation group were additionally administered with phenobarbital, and the therapeutic effects in the two groups were compared.

Results: The total treatment effective rate of patients in the observation group was significantly higher than that in the control group (P<0.05); moreover, the frequency of epileptic seizures, epilepsy integrals, and HAD scores of patients in the observation group after treatment were significantly lower than those in the control group (P<0.05), but the MoCA score was significantly higher than that in the control group (P<0.05). Positive expression quantities of IL-1β and Bax proteins in children in the observation group after treatment were significantly lower than those in the control group (P<0.05), whereas positive expression quantities of IL-6 and Bcl-2 were significantly higher than those in the control group (P<0.05).

Conclusion: Carbamazepine-phenobarbital combined treatment can reduce IL-1β and Bax expression levels but increase IL-6 and Bcl-2 expression levels in children with epilepsy; moreover, it can protect neurons, relieve neuronal damage, improve anxiety and depression degrees and cognitive function, and reduce the frequency of epileptic seizures. Moreover, the combined treatment offers significant clinical effects, as well as promotion and application values.

Author(s): Pi-qiang Zhang, Hong Liu, Hong-Juan Li
Abstract | Full-Text | PDF

Share this